Category: Treatments

In “Fight Asbestosis Inflammation to Prevent Mesothelioma from Forming ” researchers identified chronic inflammation from asbestosis as a risk for developing mesothelioma. Below are some suggestions from the book “Life Over Cancer” by Keith I. Block, M.D., for managing inflammation through diet. For patients battling asbestosis, making some dietary changes may not only lead to …

At The Block Center for Integrative Cancer Treatment, Dr. Keith Block, MD, offers cancer patients an innovative method to receive chemotherapy that takes advantage of an individual’s circadian rhythms and allows patients to receive their chemotherapy at a time when it will be most effective and least toxic. The delivery of chronomodulated chemotherapy is through …

Mesothelioma can be a painful cancer. Over half of the pleural mesothelioma patients experience pain in the chest which can be intense and severe enough to require narcotics to alleviate the pain and discomfort. Not willing to take any more drugs, some mesothelioma patients are turning to hypnosis as a way to manage their pain. …

Researchers are seeking 40 patients that have confirmed malignant mesothelioma, who are not candidates for surgery or radiation, to test the drug gefitinib. Gefitinib inhibits cellular growth in cancerous cells by targeting the proteins. The trade name for gefitinib is Iressa. Malignant mesothelioma is a cancer caused by exposure to airborne asbestos fibers. The fibers …

Even as recent advances in the treatment of malignant mesothelioma have led to a better long-term prognosis for some patients, physicians have not been able to definitely determine which patient classes have the best overall chances at long-term survival. Early diagnosis and epitheloid histology are typically seen as the best prognostic factors, but variations even …

Source: Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma Most patients with malignant mesothelioma are only diagnosed with the disease in its later stages, when treatment options are generally limited to systemic chemotherapy. For these patients, combination therapy with pemetrexed and cisplatin is the …

Article: Surgery for Malignant Pleural Mesothelioma Malignant mesothelioma is one of the most difficult diseases in all of medicine to manage effectively. Median survival time typically averages only 12-14 months. For patients lucky enough to receive a diagnosis in the disease’s earliest stages, median survival can sometimes be extended two or three years, but a …

Source: New Scientist New Scientist is running a story on an investigational cancer treatment that cured 90% of the mice who received the therapy. The treatment involved “reprogramming” the mice’s immune system to identify the cancer as an antigen and then attack it as such. The study’s authors claim that variations on the therapy could …

Source: Post-Bulletin The Minnesota Post-Bulletin is running an article on the Minnesota Partnership for Biotechnology and Medical Genomics, a research partnership comprised of the Mayo Clinic, the University of Minnesota, and the State of Minnesota. The Partnership’s goal is to position Minnesota as a leader in medical research by developing innovative diagnostic and treatment strategies …

Source: BTG Life sciences company BTG has licensed its experimental anti-cancer compound, BGC 945, to Onxy pharmaceuticals, who will further develop and commercialize the compound. BGC 945 is an anti-cancer agent in the class of compounds known as TS inhibitors—compounds which derive their cancer treatment effects from the inhibition of thymidylate synthase (TS), an enzyme …